XERIS BIOPHARMA HOLDINGS, INC. Operating Income
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Operating Income of $5.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. operating income (loss) for the quarter ending 2026-06-30 was $5.17M, a 15.42% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating income (loss) for the quarter ending 2026-03-31 was $7.92M.
- XERIS BIOPHARMA HOLDINGS, INC. operating income (loss) for the quarter ending 2025-12-31 was $16.77M, a 898.99% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating income (loss) for the quarter ending 2025-09-30 was $6.73M.
- XERIS BIOPHARMA HOLDINGS, INC. operating income (loss) for fiscal 2025 was $24.90M.
- XERIS BIOPHARMA HOLDINGS, INC. operating income (loss) for fiscal 2024 was -$33.65M.
- XERIS BIOPHARMA HOLDINGS, INC. operating income (loss) for fiscal 2023 was -$44.01M.
- XERIS BIOPHARMA HOLDINGS, INC. operating income (loss) for fiscal 2022 was -$81.94M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.17M 10-Q · filed 2026-08-06 | $13.09M 10-Q · filed 2026-08-06 | $29.86M derived: sum of 3 quarters · filed 2026-08-06 | $36.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.92M 10-Q · filed 2026-05-07 | $24.69M derived: sum of 2 quarters · filed 2026-05-07 | $31.42M derived: sum of 3 quarters · filed 2026-05-07 | $35.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $16.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $23.50M derived: sum of 2 quarters · filed 2026-03-02 | $27.99M derived: sum of 3 quarters · filed 2026-08-06 | $24.90M 10-K · filed 2026-03-02 |
| 2025-09-30 | $6.73M 10-Q · filed 2025-11-06 | $11.21M derived: sum of 2 quarters · filed 2026-08-06 | $8.12M 10-Q · filed 2025-11-06 | $9.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.48M 10-Q · filed 2026-08-06 | $1.39M 10-Q · filed 2026-08-06 | $3.07M derived: sum of 3 quarters · filed 2026-08-06 | -$9.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$3.09M 10-Q · filed 2026-05-07 | -$1.41M derived: sum of 2 quarters · filed 2026-05-07 | -$14.30M derived: sum of 3 quarters · filed 2026-05-07 | -$22.49M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$11.21M derived: sum of 2 quarters · filed 2026-03-02 | -$19.40M derived: sum of 3 quarters · filed 2026-03-02 | -$33.65M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$12.89M 10-Q · filed 2025-11-06 | -$21.08M derived: sum of 2 quarters · filed 2025-11-06 | -$35.33M 10-Q · filed 2025-11-06 | -$45.17M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$8.19M 10-Q · filed 2025-08-07 | -$22.43M 10-Q · filed 2025-08-07 | -$32.27M derived: sum of 3 quarters · filed 2026-03-02 | -$37.19M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$14.24M 10-Q · filed 2025-05-08 | -$24.09M derived: sum of 2 quarters · filed 2026-03-02 | -$29.00M derived: sum of 3 quarters · filed 2026-03-02 | -$44.98M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$9.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$14.75M derived: sum of 2 quarters · filed 2026-03-02 | -$30.73M derived: sum of 3 quarters · filed 2026-03-02 | -$44.01M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$4.91M 10-Q · filed 2024-11-08 | -$20.89M derived: sum of 2 quarters · filed 2024-11-08 | -$34.17M 10-Q · filed 2024-11-08 | -$49.34M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$15.98M 10-Q · filed 2024-08-08 | -$29.26M 10-Q · filed 2024-08-08 | -$44.43M derived: sum of 3 quarters · filed 2025-03-06 | -$63.21M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$13.28M 10-Q · filed 2024-05-09 | -$28.45M derived: sum of 2 quarters · filed 2025-03-06 | -$47.23M derived: sum of 3 quarters · filed 2025-03-06 | -$66.14M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$15.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$33.95M derived: sum of 2 quarters · filed 2025-03-06 | -$52.87M derived: sum of 3 quarters · filed 2025-03-06 | -$81.94M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$18.78M 10-Q · filed 2023-11-09 | -$37.70M derived: sum of 2 quarters · filed 2023-11-09 | -$66.77M 10-Q · filed 2023-11-09 | -$115.04M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$18.92M 10-Q · filed 2023-08-08 | -$47.99M 10-Q · filed 2023-08-08 | -$96.26M derived: sum of 3 quarters · filed 2024-03-06 | -$120.62M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$29.07M 10-Q · filed 2023-05-09 | -$77.34M derived: sum of 2 quarters · filed 2024-03-06 | -$101.70M derived: sum of 3 quarters · filed 2024-03-06 | -$127.49M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$48.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$72.63M derived: sum of 2 quarters · filed 2024-03-06 | -$98.42M derived: sum of 3 quarters · filed 2024-03-06 | -$115.16M 10-K · filed 2024-03-06 |
| 2021-09-30 | -$24.36M 10-Q · filed 2022-11-09 | -$50.15M derived: sum of 2 quarters · filed 2022-11-09 | -$66.89M 10-Q · filed 2022-11-09 | -$86.23M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$25.79M 10-Q · filed 2022-08-10 | -$42.53M 10-Q · filed 2022-08-10 | -$61.87M derived: sum of 3 quarters · filed 2022-08-10 | -$75.61M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$16.74M 10-Q · filed 2022-05-11 | -$36.08M derived: sum of 2 quarters · filed 2022-05-11 | -$49.83M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$19.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$33.09M derived: sum of 2 quarters · filed 2022-03-11 | -$83.55M 10-K · filed 2022-03-11 | |
| 2020-09-30 | -$13.74M 10-Q · filed 2021-11-10 | -$64.20M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |